HYPERPROLACTINEMIA AND OVERWEIGHT

The metabolic role of prolactin has become a relevant topic in recent years. It has been established that an excess of prolactin (PRL) leads to increased body weight, obesity, metabolic syndrome, and disturbances in glucose-insulin and lipid profiles. This is mainly attributed to the suppression of physiological dopaminergic tone. Research has shown that prolactin receptors and dopamine receptors are expressed in both pancreatic β-cells and adipose tissue, confirming the essential role of prolactin and dopamine in peripheral metabolic regulation. Medical treatment with dopamine agonists, such as bromocriptine and cabergoline, helps reduce metabolic syndrome and obesity, as well as significantly improve glucose-insulin and lipid profiles.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-03-10
DOI
https://doi.org/10.5281/zenodo.14997941
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HYPERPROLACTINEMIA AND OVERWEIGHT

Zenodo (CERN European Organization for Nuclear Research)
Growth Hormone and Insulin-like Growth Factors
article

HYPERPROLACTINEMIA AND OVERWEIGHT

article en

Abstract

The metabolic role of prolactin has become a relevant topic in recent years. It has been established that an excess of prolactin (PRL) leads to increased body weight, obesity, metabolic syndrome, and disturbances in glucose-insulin and lipid profiles. This is mainly attributed to the suppression of physiological dopaminergic tone. Research has shown that prolactin receptors and dopamine receptors are expressed in both pancreatic β-cells and adipose tissue, confirming the essential role of prolactin and dopamine in peripheral metabolic regulation. Medical treatment with dopamine agonists, such as bromocriptine and cabergoline, helps reduce metabolic syndrome and obesity, as well as significantly improve glucose-insulin and lipid profiles.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 42%
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HYPERPROLACTINEMIA AND OVERWEIGHT · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS